This National Cooperative Vaccine Development Groups for AIDS contains two Research Projects that propose to further develop and study four types of novel vaccine candidates for HIV and SIV. The candidate vaccines under development in Project 1 include recombinant stress fusion proteins, genome-less retroviral particles and live recombinant BCG vehicles expressing antigens and lymphokines. The candidate vaccines under development in Project 2 are centered on genetically modified autologous antigens presenting cells that produce both antigens and lymphokines. A central theme in the research underway in this NCVDG is the development of vaccines that deliver a combination of selected antigens and lymphokines to the sites of antigen presentation. Our strategy is to genetically engineer these candidate vaccines, to investigate the immune responses, to compare the ability of these reagents to elicit specific immune responses, and to provide these reagents to other investigators for further studies in primates. An interactive group of consultants and collaborators has been established to support this NCVDG. Collaborative interactions have also been established with other NCVDGs to enable testing of the immunogenicity and protective efficacy of selected vaccine candidates in primates. Our objective is to improve our repertoire of vaccine reagents that have well-characterized abilities to elicit strong and long lived immune responses to HIV. Our long term goal is to develop an efficacious AIDS vaccine.
| Segal, A H (1996) Anatomic predilection of the spondyloarthropathies(-)a case of the nerves? J Rheumatol 23:491-4 |
| Burns, D P; Collignon, C; Desrosiers, R C (1993) Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J Virol 67:4104-13 |
| Burns, D P; Desrosiers, R C (1992) A caution on the use of SIV/HIV gag antigen detection systems in neutralization assays. AIDS Res Hum Retroviruses 8:1189-92 |
| Javaherian, K; Langlois, A J; Schmidt, S et al. (1992) The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 89:1418-22 |
| Kim, S; Ikeuchi, K; Groopman, J et al. (1990) Factors affecting cellular tropism of human immunodeficiency virus. J Virol 64:5600-4 |
| Kim, S; Ikeuchi, K; Byrn, R et al. (1989) Lack of a negative influence on viral growth by the nef gene of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 86:9544-8 |
